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S U M M A R Y
Background: Intensive care unit (ICU)-acquired pneumonia and ventilator-associated pneumonia (VAP)
are associated with poor clinical and economic outcomes. Data regarding ICU-acquired pneumonia and
VAP are not readily available from developing countries, including China. The objective of this meta-
analysis was to evaluate the incidence, mortality rate, length of stay, and pathogens associated with ICU-
acquired pneumonia in China.
Methods: A meta-analysis and systematic review of 334 publications published between January
2007 and May 2012 and retrieved from the Chinese BioMedical database, China National Knowledge
Infrastructure, VIP Chinese Science and Technique Journals database, Wanfang database, and PubMed
was conducted.
Results: The incidences of ICU-acquired pneumonia and VAP were 16.2% (95% conﬁdence interval (CI)
12.8–20.4%) and 33.7% (95% CI 31.4–36.1%), respectively; mortality rates were 37.4% (95% CI 24.6–52.2%)
and 34.5% (95% CI 29.2–40.1%), respectively. The durations of stay in the ICU and hospital were 12.4 (95%
CI 9.6–15.3) and 17.7 (95% CI 15.6–19.7) days and 18.0 (95% CI 16.5–19.6) and 30.5 (95% CI 26.4–34.7)
days for ICU-acquired pneumonia and VAP, respectively. Pseudomonas aeruginosa (19.9%) and
Acinetobacter baumannii (13.9%) were the most frequently isolated pathogens, followed by Klebsiella
pneumoniae (11.9%) and Staphylococcus aureus (10.4%); 82.9% of S. aureus isolates were reported to be
methicillin-resistant.
Conclusions: ICU-acquired pneumonia/VAP remains a major cause of morbidity and mortality in patients
in the ICU in China. Data on organisms causing disease in this population could help guide appropriate
prevention strategies and treatment.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Pneumonia is a common nosocomial infection in intensive care
units (ICUs). According to the American Thoracic Society guidelines,
approximately 90% of cases of nosocomial ICU-acquired pneumonia
occur in patients requiring mechanical ventilation (MV).1 Ventila-
tor-associated pneumonia (VAP) is a serious complication in
patients receiving MV.2 ICU-acquired pneumonia and VAP are* Corresponding author.
E-mail address: mkyaw11@gmail.com (M.H. Kyaw).
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http://dx.doi.org/10.1016/j.ijid.2014.05.030
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).associated with poor clinical and economic outcomes, including
increased morbidity and mortality,3–5 substantially increased
hospital length of stay (LOS),3,6 and increased duration of MV.3
The bacterial pathogens Pseudomonas aeruginosa, Escherichia coli,
Staphylococcus aureus, and Klebsiella pneumoniae are common causes
of ICU-acquired pneumonia/VAP globally1,7 and are associated with
substantial morbidity and mortality in the ICU.8,9 Despite the high
prevalence, few results from ICU-acquired pneumonia/VAP studies are
readily available from developing countries, including China.6 The
objective of this meta-analysis was to evaluate the incidence, mortality
rate, LOS, and pathogens associated with ICU-acquired pneumonia in
China using a systematic search of key Chinese medical databases in
conjunction with PubMed.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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2.1. Study selection
The systematic literature search was limited to studies with
publication dates between January 2007 and May 2012 and
included the following databases: Chinese BioMedical Database
(CBM), China National Knowledge Infrastructure (CNKI), Chinese
Science and Technique Journals Database (VIP; http://www.cqvip.-
com), Wanfang database (http://www.wanfangdata.com/), and
PubMed.
Search terms in the title, summary, and keywords included
ventilator-associated/mechanical ventilation/or ICU and pneumo-
nia for the CBM, CNKI, Wanfang, and VIP databases. For PubMed,
medical subject heading (MeSH) terms and all ﬁelds were
searched: (‘‘intensive care units’’[MeSH Terms] OR ‘‘intensive care
units’’[All Fields] OR ‘‘intensive care unit’’[All Fields] OR ‘‘ICU’’[All
Fields]) AND (‘‘pneumonia’’[MeSH Terms] OR ‘‘pneumonia’’[All
Fields]) AND (‘‘china’’[MeSH Terms] OR ‘‘china’’[All Fields] OR
‘‘Chinese’’[All Fields] OR ‘‘Chinese mainland’’[All Fields]) AND
(‘‘2007/01/01’’[PDAT]: ‘‘2012/04/10’’[PDAT]). The full electronic
search strategy is presented in the Supplementary Material
(Figure S1).
2.2. Outcomes of interest
Publications were evaluated for key study criteria of interest,
which included the time of onset of infection, total number and
proportion of ICU patients, mean LOS, in-hospital mortality rate,
and the identiﬁcation of organisms isolated for ICU-acquired
pneumonia/VAP.
2.3. Inclusion and exclusion criteria
For inclusion, it was required that the study was conducted in
China and that the subjects had ICU-acquired pneumonia or VAP.
Studies included randomized clinical trials (RCTs), nested case–
control studies, retrospective or prospective cohort studies, and
surveillance studies. Selected studies reported any of the following
outcomes: incidence and mortality rate of ICU-acquired pneumo-
nia and/or VAP; time of onset and duration of ICU-acquired
pneumonia and/or VAP; LOS; pathogens associated with the
development of ICU-acquired pneumonia and/or VAP. Duplicate
studies conducted in the same population (most relevant
publication chosen for analysis), studies in patients who had
community-acquired pneumonia before they were hospitalized in
the ICU, and systematic reviews/meta-analyses were excluded.
ICU-acquired pneumonia was deﬁned in accordance with the
standards of the People’s Republic of China issued by the Ministry
of Health regarding hospital infection in the clinical diagnostic
criteria;10 this deﬁnition is equivalent to the American Thoracic
Society deﬁnition of hospital-acquired pneumonia, i.e., ‘‘pneumo-
nia that occurs 48 hours or more after admission, which was not
incubating at the time of admission’’,1 with the exception that the
cases be managed in the ICU. VAP was deﬁned according to the US
Centers for Disease Control and Prevention as pneumonia in people
who have a device to continuously assist with or control
respiration through a tracheostomy or by endotracheal intubation
within 48 h before the onset of infection, inclusive of the weaning
period.11 The time of onset of VAP was calculated beginning with
the ﬁrst use of a respirator.
2.4. Literature screening and data extraction
The review and analysis of studies involved the screening of
potential publications, extraction of relevant data, qualityassessment, and the subsequent analysis of the data. Literature
reviewers were divided into two groups that worked in parallel;
all reviewers received identical instruction. Reviewers indepen-
dently screened the literature by title, keywords, and abstract
according to the inclusion and exclusion criteria. The full texts of
potentially relevant publications were obtained and re-evaluat-
ed by the same investigators. Any discrepancies between
ﬁndings from the two groups of reviewers were adjudicated
by a third reviewer.
2.5. Quality assessment
Although reporting measures of study quality in meta-analyses
already exist and are widely used,12,13 these scales are speciﬁc to
the speciﬁc type of study. In this meta-analysis, various types of
study were included. Therefore, we could not use a pre-existing
scale. Thus, we developed a study-speciﬁc eight-item quality
rating scale: (1) Was primary disease reported? (2) Were diagnosis
criteria of pneumonia reported? (3) Were inclusion and exclusion
criteria of cases reported? (4) Was the source of cases reported? (5)
Were cases correctly included based on the reported method? (6)
Was the source of specimens reported? (7) Was the method of
sampling specimens reported? (8) Was the method of pathogenic
bacteria testing reported? Each item was scored on a three-point
scale, with 0 indicating poorest quality, 1 indicating middle
quality, and 2 indicating better quality. The scores for each item
were then added to give a composite score for the study. Questions
1 through 5 were used for the quality evaluation of studies that
reported outcomes except for pathogenic bacteria reporting, with a
highest total score of 10. If the total score was 8, the study was
regarded as ‘good’ quality. Questions 6 through 8 were used for
quality evaluation of studies that reported pathogenic bacteria
culture. Thus, the highest possible total score, indicating highest
quality, was 6. If the total score was 5, the study was regarded as
‘good’ quality in the section on pathogenic bacteria reporting.
2.6. Statistical analysis
EpiData 3.1 (EpiData Association, Odense, Denmark) was used
to gather data after initial data extraction, and NoteExpress 2
(Aegean Software Corporation, Shanghai, China) was used for
literature management. MetaAnalyst (beta 3.13; http://tuftscaes.
org/meta_analyst) was used for pooled proportions and odds
ratios. A sensitivity analysis was conducted to examine the impact
of methodological quality if only high quality studies were
included. The random effect model of the DerSimonian–Laird
method was used in all analyses because it provides a more
conservative estimate (i.e., with wider conﬁdence intervals (CI))
than the ﬁxed effect model.14 Studies were generally weighted in
favor of those with more precise results (narrower CIs).15
Publication bias was assessed using Stata 12.0 (StataCorp LP,
Texas, USA) and Egger’s test.
Nested case–control studies were published as case–controls
but were nested within a larger cohort study. The denominator for
those calculations included all enrolled patients and the numerator
was equal to only those with the characteristic being investigated
(e.g., ICU-acquired pneumonia) within all enrolled patients. For
ICU-acquired pneumonia, the incidence rate was calculated as the
number of patients with ICU-acquired pneumonia/total number of
patients admitted to the ICU; the incidence rate for VAP was
calculated as the number of patients with VAP/total number of
patients who received ventilation. Because the incidence propor-
tion was reported in most of the studies included, we used the
incidence proportion of ICU-acquired pneumonia as representative
of the incidence rate. The incidence proportion is a measure or
estimate of ‘average risk’.16
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3.1. Study inclusion
A total of 22 583 publications were identiﬁed from the database
search, and of these, 334 were included in the quantitative
synthesis (Figure 1; see Supplementary Material Table S1 for
information on speciﬁc publications). Of these 334 publications,
236 included patients 18 years of age and 51 included patients
<18 years of age. An additional 47 publications included patients
of all ages; these were counted in the group that included patients
18 years of age because most of the populations discussed
primarily comprised adults. After evaluation, 255 (out of 334)
publications were included in the quality evaluation with
questions 1–5 (Figure 2), with a mean  standard deviation (SD)
score of 7.3  1.8. One hundred and ﬁfty-two publications reported
pathogenic bacteria culture and were eligible for quality evaluation
with questions 6–8 (Figure 2), with a mean  SD score of 4.0  1.2.
3.2. Time to onset of VAP
Eighteen publications including 871 patients reported time to
VAP onset. The mean weighted time from the use of a ventilator to
onset of VAP was 6.7 (95% CI 6.0–7.3) days. When stratiﬁed by age,
the mean onset of VAP was 4.8 (95% CI 3.6–6.0) days among
subjects <18 years of age and 6.9 (95% CI 6.2–7.7) days among
subjects 18 years of age.
3.3. Incidence of ICU-acquired pneumonia and VAP
A total of 235 publications reported the incidence of pneumo-
nia, which was stratiﬁed into three mutually exclusive categories:22 583 record s idenﬁe d 
through dat abase  search
17 989 record s removed  as 
non-Chinese  core  jour nals
4594 r ecords 2943 record s removed  as 
duplicates
1651 rec ords scree ned on  bas is 
of tle  and  abstract
594 re cords  exclud ed
Not relevan t to the  study 
1057 full-text  arcles  assessed 
for eli gibility
723 ar cles  exclud ed base d on  full  text 
Reasons for exclu sion: 
348 irrelevan t 
207 not IC U pneumoni a 
90 gu idelines  and  curre nt medical 
prac ce 
53 low quali ty bec ause  of  unclear 
objecves and method s 
20 VAP bu t no t speciﬁ ed whet her 
paents wer e in  th e IC U 
 Fungal  pn eumonia 
1 paent  wa s colonized  or in fecte d 
334 studies  included  in 
quantave  sy nthes is 
(meta-a nalys is)
Onset  me in  18  record s 
Incid ence in  235 rec ords 
Length of  stay  24  records 
Mortality  rate  in 47  record s 
Isolated  organ isms  in 152 records
Figure 1. Flow diagram of the literature search and article selection.patients in the ICU with ICU-acquired pneumonia (n = 45), patients
in the ICU with VAP (publication did not specify whether the data
included only patients who had used a respirator; n = 15), and
patients with VAP concomitant with respirator use in the ICU
(n = 178); three publications reported two categories of incidences.
Incidences of pneumonia were combined, and the overall
incidence of pneumonia was 16.2% (95% CI 12.8–20.4%) for ICU-
acquired pneumonia in ICU patients, 4.6% (95% CI 3.5–5.9%) for VAP
in ICU patients, and 33.7% (95% CI 31.4–36.1%) for VAP-associated
respirator use in the ICU (Table 1). In each category, the incidence
rates for pneumonia were further stratiﬁed by age and study type
(Table 1). Egger’s test showed no publication bias when verifying
the 178 publications that included patients with VAP concomitant
with respirator use in the ICU (0.21, 95% CI 0.64 to 0.23,
p = 0.346).
3.4. Length of stay in the hospital and ICU
A total of 24 publications reported LOS endpoints; three studies
reported two types of in-hospital stay. LOS in all publications was
combined and weighted by sample size. LOS in the hospital for
ICU-acquired pneumonia was 17.7 (95% CI 15.6–19.7) days and for
ICU-acquired VAP was 30.5 (95% CI 26.4–34.7) days. LOS in the ICU
for ICU-acquired pneumonia was 12.4 (95% CI 9.6–15.3) days and
for VAP was 18.0 (95% CI 16.5–19.6) days.
3.5. In-hospital mortality
Pneumonia-related fatalities were reported in 47 publications
(Table 2). Two endpoints were reported: (1) the number of
deaths in patients with ICU-acquired pneumonia among the
number of patients with ICU-acquired pneumonia, and (2) the
number of deaths in ICU patients with VAP among the total
number of ICU patients with VAP. Fatalities in all publications
were combined and weighted by sample size. The mortality rate
was 37.4% (95% CI 24.6–52.2%) for ICU-acquired pneumonia and
34.5% (95% CI 29.2–40.1%) for VAP in the ICU. In each category,
the incidence rates for death were further stratiﬁed by age, as
shown in Table 2.
3.6. Organisms isolated
Laboratory data identifying pathogenic bacteria were reported
in 152 publications, with two publications reporting both
ICU-acquired pneumonia and ICU VAP. These studies identiﬁed
ICU-acquired pneumonia (n = 35) and ICU VAP (n = 119). The
numbers, proportions, and types of pathogens associated with ICU
pneumonia and VAP are reported in Table 3. These data were
further stratiﬁed by patient age and weighted by sample size.
P. aeruginosa was the most frequently isolated pathogen in our
analysis (19.9%, 95% CI 18.6–21.3%), followed by Acinetobacter
baumannii (13.9%, 95% CI 12.6–15.4%), then K. pneumoniae and
S. aureus (Table 3). K. pneumoniae and E. coli accounted for a higher
proportion of infections in patients <18 years of age (19.8%, 95% CI
16.8–23.1%, and 9.8%, 95% CI 8.1–11.9%, respectively) compared
with those 18 years of age (10.3%, 95% CI 9.4–11.3%, and 7.3%, 95%
CI 6.5–8.2%, respectively). P. aeruginosa accounted for 20.6% (95% CI
19.2–22.0%), A. baumannii accounted for 15.0% (95% CI 13.5–
16.6%), K. pneumoniae accounted for 12.1% (95% CI 11.0–13.2%),
and S. aureus accounted for 10.3% (95% CI 9.3–11.3%) of VAP
acquired in the ICU (Table 3). S. aureus and P. aeruginosa were
responsible for a lower proportion of infections in patients <18
years of age (4.0%, 95% CI 2.7–5.8%, and 14.3%, 95% CI 11.4–17.9%,
respectively) compared with those 18 years of age (11.8%, 95% CI
10.79–12.8%, and 21.1%, 95% CI 19.7–22.7%, respectively). Using data
from 19 studies, the weighted proportion of methicillin-resistant
Included 33 4 studies
255 papers reported other outcomes 
(e.g. inc idenc e, fatality  rate, onset me , 
etc.)  and/or not pa thogens
73 reported other 
outcome s and  
pathogens
182 repo rted oth er 
outcomes except  for 
pathogens 
79 arcles reported 
pat hogens only
152 ar cles were  evaluated by quesons 6-8 that
focused on pat hog ens: 
6. Repo rted sou rce of spec ime ns? 
7. Reported method of  sampling  specimens? 
8. Reported  method of  pathogenic bacteria test? 
255 were eval uated by queso ns 1–5 that  focused 
on cas es: 
1. Reported pr imary disease? 
2. Reported diagnosis cr iteria of  pneumonia? 
3. Reported inc lus ion  and exclus ion  cr iteria of 
cases? 
4. Repo rted sou rce of  ca ses?  
5. Included ca ses  based on  the reported  method 
correctly? 
Figure 2. Flow diagram of the methodological quality evaluation.
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pneumonia and VAP was 82.9% (95% CI 69.0–91.4%).
3.7. Sensitivity analysis
In the sensitivity analysis, the conclusions remained robust.
When only ‘good’ quality studies were evaluated, the outcomes did
not alter dramatically. The overall incidence of pneumonia was
20.5% (95% CI 11.4–34.0%) for ICU-acquired pneumonia in ICU
patients (n = 11) and 35.5% (95% CI 32.3–38.9%) for VAP-associated
respirator use in the ICU (n = 104). The mortality rate was 31.2%
(95% CI 27.0–35.7%) for ICU-acquired pneumonia (n = 2) and 36.3%
(95% CI 29.7–43.4%) for VAP in the ICU (n = 29). P. aeruginosa was
also the most frequently isolated pathogen (19.3%, 95% CI 17.5–
21.2%), followed by A. baumannii (13.6%, 95% CI 11.9–15.6%)
(n = 77).
4. Discussion
This systematic review of 334 Chinese-language publications
evaluated the onset, incidence, LOS, mortality rate, and pathogens
associated with ICU-acquired pneumonia/VAP in China. In our
analysis, the mean onset of VAP after MV was approximately
7 days, suggesting that the majority of VAP in China is late onset,
although we did not make a formal distinction between early- and
late-onset VAP in our analysis. Of relevance, VAP onset in China is
similar to the 7- to 9-day onset reported in the English-language
literature.17,18
In our analysis, the incidence of ICU-acquired pneumonia was
16%, which is different from ﬁndings from one of the few
prospective studies reporting ICU-acquired pneumonia ratesoutside of the USA.19 The prospective study of Eurasian ICUs by
Alp et al.19 reported a 7% rate of pneumonia. When stratifying the
incidence rate by age, our analyses demonstrated a lower
incidence of ICU-acquired pneumonia among patients <18 years
of age compared with patients aged 18 years. This difference was
inﬂuenced by three publications that reported incidences in
children ranging from 2% to 3%, which is substantially lower than
in other studies.20–22 Among patients in the ICU receiving MV, the
incidence of VAP ranged from 20.5% (retrospective cohort) to 43.5%
(nested case–control studies) depending on the study type
assessed. For reference, a systematic review of English-language
observational studies and randomized trials that provided
incidences of VAP by Safdar et al.2 reported a range of 9.7%
(cohort, non-randomized trials) to 22.8% (comparator arms of
RCTs) also in patients in the ICU receiving MV. Despite the
commonalities of the patient populations in our analysis and that
of Safdar et al.,2 the reports differ with respect to the time frame
analyzed (2007–2012 vs. 1991–2004, respectively) and other
factors. Overall, ventilator use was common in the ICU in China; Hu
et al.23 estimated 43% use across seven ICUs in Shanghai. These
data, coupled with the fact that approximately 90% of ICU-acquired
pneumonia occurs in patients receiving MV, support the relatively
high incidence rate reported in our analysis.1
In this analysis, hospital LOS was shorter for patients with ICU-
acquired pneumonia compared with ICU-acquired VAP (mean
18 vs. 31 days, respectively); ICU LOS was similarly shorter for
those with ICU-acquired pneumonia vs. VAP (mean 12 vs. 18 days).
VAP-associated LOS in our study was longer than that reported in
the 2011 China Health Ministry Statistical Yearbook,24 which
estimated hospital stays of 10.5 days in patients with any disease
in any hospital ward. This trend for increased hospitalization with
Table 1









ICU-acquired pneumonia in ICU patients
Age, years
<18 7 382 6748 5.2 (3.2–8.3)
18 38 3444 18 898 19.7 (15.6–24.6)
Study type
Case series 18 1825 12 938 15.6 (10.8–22.1)
Nested case–controla 5 927 2507 29.2 (17.6–44.2)
Non-RCT 2 68 416 19.9 (9.7–36.5)
Prospective cohort 2 98 1187 12.3 (4.4–30.0)
RCT 4 52 205 25.2 (17.0–35.7)
Surveillance 14 856 8393 12.2 (8.5–17.1)
Subtotal 45 3826 25 646 16.2 (12.8–20.4)
VAP in ICU patients
Age, years
<18 3 45 2767 1.7 (1.2–2.5)
18 12 17 804 620 122 5.5 (4.1–7.3)
Study type
Case series 1 51 575 8.9 (6.8–11.5)
Non-RCT 4 524 19 474 4.3 (0.9–18.0)
Prospective cohort 1 868 12 105 7.2 (6.7–7.6)
Surveillance 9 16 406 590 735 4.1 (3.1–5.4)
Subtotal 15 17 849 622 889 4.6 (3.5–5.9)
VAP with respirator use in ICU
Age, years
<18 31 1721 4904 37.2 (31.8–42.9)
18 147 8043 30 999 33.1 (30.6–35.7)
Study type
Case series 46 3401 11 382 36.2 (31.7–41.0)
Nested case–control 16 913 2254 43.5 (36.9–50.3)
Non-RCT 27 1381 6864 25.5 (20.6–30.9)
Prospective cohort 8 1176 5141 32.6 (24.0–42.6)
RCT 73 2382 6699 35.4 (32.6–38.3)
Retrospective cohort 1 18 88 20.5 (13.3–30.2)
Surveillance 8 599 3730 23.2 (11.5–41.2)
Subtotal 178 9764 35 903 33.7 (31.4–36.1)
CI, conﬁdence interval; ICU, intensive care unit; RCT, randomized controlled trial;
VAP, ventilator-associated pneumonia.
a Incidence rates presented for case–control studies were calculated from those
studies that were published as case–control but were nested within a larger cohort
study.
Table 2









Deaths in patients with ICU-acquired pneumonia
Age, years
<18 0 - - -
18 3 156 472 37.4 (24.6–52.2)
Subtotal 3 156 472 37.4 (24.6–52.2)
Deaths in patients with ICU-acquired VAP
Age, years
<18 12 129 638 20.8 (17.4–24.7)
18 32 733 1869 40.4 (34.1–47.0)
Subtotal 44 862 2507 34.5 (29.2–40.1)
CI, conﬁdence interval; ICU, intensive care unit; VAP, ventilator-associated
pneumonia.
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ICU LOS among patients with VAP (26 and 12 days, respectively)
compared to patients without VAP (14 and 6 days, respectively).
When comparing the reported absolute LOS among patients with
VAP, ICU and hospital stays are generally longer among Chinese
patients compared to patients in the USA; however, the average
LOS in hospital in China24 (10.5 days in 2011) is also longer than
that in the USA25 (6.2 days in 2010), suggesting that the absolute
LOS may be more indicative of differences in hospitalizationpractices rather than differences in disease. It is also possible that
the patients’ background conditions or concomitant diseases
requiring mechanical ventilation may affect LOS.
The mortality rate was highest among patients with ICU-
acquired pneumonia (37.4%); however, patients with VAP had
comparable mortality (34.5%) and were within the previously
reported range of 24% to 76%.3,8 When the mortality rate was
stratiﬁed by age, patients aged <18 years were two to three times
less likely to die as a result of ICU-acquired pneumonia and VAP
than those aged 18 years, potentially reﬂecting the lower
incidence of infection in this group as well as potential prolonged
ventilation (e.g. chronic obstructive pulmonary disease (COPD)).
Previous studies have shown that Gram-negative bacilli are
commonly associated with VAP and are responsible for approxi-
mately 58% of VAP in the English literature8 and up to 92% in
developing countries.6 In our analysis, Gram-negative bacilli were
responsible for approximately 80% of VAP. P. aeruginosa and A.
baumannii were the most frequently isolated Gram-negative
pathogens, followed by K. pneumoniae; these data are similar to
results from other Asian countries.26 The mortality rate of VAP is
inﬂuenced by the colonizing bacteria and may be increased up to
43% in P. aeruginosa and A. baumannii infections,27 a factor that
may have inﬂuenced the rate of VAP-associated mortality
observed in this analysis. Gram-positive bacteria are generally
responsible for up to 35% of VAP, and of these, S. aureus accounts
for approximately 20% of cases.28 In our study, S. aureus was
identiﬁed in 10.3% of VAP, which is a lower rate than that reported
in Western countries.8,28 Approximately 83% of the S. aureus
samples collected from ICU patients with VAP were MRSA-
positive, which is in agreement with the 84% of MRSA-positive
samples reported by the International Nosocomial Infection
Control Consortium.29
A small difference was detected in distribution of pathogens
between the overall group and the age-based subgroups. K.
pneumoniae and E. coli accounted for a higher proportion of VAP in
children, whereas S. aureus and P. aeruginosa were found at a higher
rate in adults. These results were inconsistent in the subgroup of
patients for whom admission to the ICU was unknown because of
the small sample size and wide CIs.
This is the ﬁrst systematic review of ICU-acquired pneumonia/
VAP in China to apply rigorous screening and analysis of the quality
of the studies included. Given the potential existence of
heterogeneity, we adopted a random-effects model to pool all
related indices. This may have led to a wider 95% CI, which
provided a more conservative estimate of the overall results.
However, certain limitations should be considered when evaluat-
ing these data. To ensure robust results, we expanded the sample
size by merging original studies whenever possible. As with all
systematic reviews, the analysis is observational and based on
secondary data; therefore, it is limited by the quality of the primary
studies. However, sensitivity tests of these data from high quality
studies demonstrated a robust outcome. Moreover, a systematic
review may be constrained by search strategy, selection criteria,
and publication bias, especially when the meta-analysis includes
epidemiological studies rather than only randomized controlled
trials. In our analysis, most of the included studies were
retrospective case series, which may have led to overestimated
endpoints relative to prospective studies. Although every included
study declared that their patients were strict ICU-pneumonia/VAP
based on diagnostic standards, some of the VAP episodes reported
may actually have represented colonization rather than true VAP.
Another consideration is that, because some patients were infected
by multiple pathogens, there was not always a one-to-one
correspondence between a patient and a pathogen. Additionally,
the mortality estimates assessed in this analysis are limited by the
small sample sizes.
Table 3
Numbers and proportions (95% CI) of pathogens detected in ICU-acquired pneumonia and VAPa
Pathogens Publications, n Total (ICU-acquired
pneumonia and VAP)
ICU-acquired pneumonia VAP
n (%) 95% CI n (%) 95% CI n (%) 95% CI
Staphylococcus aureus 139 3888 (10.4) 9.5–11.4 1086 (11.0) 8.9–13.4 2802 (10.3) 9.3–11.3
Age <18 years 167 (4.0) 2.7–5.8 47 (2.6) 1.8–3.7 120 (4.8) 3.2–7.2
Age 18 years 3721 (11.8) 10.9–12.8 1039 (13.8) 11.7–16.1 2682 (11.2) 10.2–12.3
Other Staphylococcus 102 1078 (3.7) 3.1–4.3 347 (3.0) 2.1–4.2 731 (3.9) 3.2–4.7
Age <18 years 176 (5.6) 4.1–7.6 52 (3.7) 2.4–5.6 124 (6.4) 4.5–9.0
Age 18 years 902 (3.1) 2.7–4.0 295 (2.8) 1.9–4.3 607 (3.4) 2.7–4.2
Streptococcus pneumoniae 29 152 (0.7) 0.6–0.9 58 (0.8) 0.5–1.3 94 (0.7) 0.5–0.9
Age <18 years 45 (1.8) 1.4–2.3 26 (1.5) 1.0–2.1 19 (2.1) 1.5–3.1
Age 18 years 107 (0.6) 0.4–0.8 32 (0.6) 0.3–1.2 75 (0.6) 0.4–0.8
Other Gram-positive pathogens 86 811 (2.7) 2.2–3.2 218 (1.6) 1.0–2.5 593 (3.0) 2.5–3.6
Age <18 years 190 (4.5) 3.0–6.6 56 (1.3) 0.3–5.2 134 (5.5) 3.6–8.2
Age 18 years 621 (2.4) 1.9–2.9 162 (1.5) 0.9–2.6 459 (2.7) 2.2–3.3
Pseudomonas aeruginosa 153 7100 (19.9) 18.6–21.3 1864 (18.2) 14.9–21.9 5236 (20.6) 19.2–22.0
Age <18 years 688 (14.3) 11.4–17.9 356 (13.5) 6.8–25.0 332 (14.7) 11.8–18.1
Age 18 years 6412 (21.1) 19.7–22.7 1508 (19.0) 15.4–23.2 4904 (21.9) 20.4–23.3
Acinetobacter baumannii 131 5232 (13.9) 12.6–15.4 1027 (11.2) 8.6–14.4 4205 (15.0) 13.5–16.6
Age <18 years 548 (11.1) 8.1–15.1 314 (18.2) 10.2–30.9 234 (10.0) 7.1–13.8
Age 18 years 4684 (14.4) 12.9–16.0 713 (10.3) 8.1–13.1 3971 (16.1) 14.4–17.9
Klebsiella pneumoniae 148 4009 (11.9) 10.9–12.9 1086 (11.2) 9.3–13.3 2923 (12.1) 11.0–13.2
Age <18 years 698 (19.8) 16.8–23.1 259 (13.9) 11.1–17.2 439 (21.7) 18.2–25.6
Age 18 years 3311 (10.3) 9.4–11.3 827 (10.5) 8.3–13.1 2484 (10.3) 9.4–11.3
Escherichia coli 131 2418 (7.6) 6.9–8.5 826 (8.8) 7.1–10.8 1592 (7.3) 6.5–8.3
Age <18 years 432 (9.8) 8.1–11.9 236 (11.1) 7.9–15.3 196 (9.2) 7.1–11.8
Age 18 years 1986 (7.3) 6.5–8.2 590 (8.5) 6.5–10.9 1396 (7.0) 6.1–8.0
Stenotrophomonas maltophilia 105 1839 (5.4) 4.7–6.2 561 (4.4) 3.1–6.2 1278 (5.9) 5.2–6.7
Age <18 years 126 (3.6) 2.6–4.9 62 (3.3) 2.2–4.9 64 (3.5) 2.3–5.4
Age 18 years 1713 (5.9) 5.1–6.8 499 (5.0) 3.4–7.1 1214 (6.3) 5.5–7.3
Enterobacter cloacae 91 769 (3.1) 2.6–3.6 221 (2.5) 1.8–3.5 548 (3.2) 2.7–3.9
Age <18 years 182 (5.1) 3.9–6.6 67 (3.2) 10.6–6.5 115 (5.5) 4.1–7.4
Age 18 years 587 (2.6) 2.1–3.1 154 (2.3) 1.6–3.4 433 (2.7) 2.1–3.3
Burkholderia cepacia 29 303 (1.0) 0.7–1.2 85 (0.8) 0.5–1.3 218 (1.0) 0.8–1.4
Age <18 years 45 (1.1) 0.6–1.8 21 (0.6) 0.1–2.6 24 (1.1) 0.6–2.2
Age 18 years 258 (0.9) 0.7–1.2 64 (0.8) 0.4–1.4 194 (1.0) 0.7–1.4
Other Gram-negative pathogens 103 2554 (5.8) 4.9–6.8 782 (6.8) 4.9–9.3 1772 (5.5) 4.6–6.6
Age <18 years 545 (10.0) 7.5–13.3 321 (12.4) 6.4–22.7 224 (9.5) 7.0–12.9
Age 18 years 2009 (4.9) 4.0–5.9 461 (5.5) 3.8–8.1 1548 (4.6) 3.7–5.8
Fungi 120 2262 (7.3) 6.3–8.3 614 (7.0) 5.3–9.1 1648 (7.4) 6.3–8.6
Age <18 years 276 (5.5) 3.9–7.6 165 (7.1) 3.8–13.0 111 (4.9) 3.3–7.2
Age 18 years 1986 (7.7) 6.6–8.9 449 (6.8) 4.9–9.2 1537 (8.0) 6.7–9.5
Other pathogens 28 715 (1.0) 0.8–1.3 326 (1.3) 0.7–2.2 389 (1.0) 0.8–1.4
Age <18 years 90 (1.4) 0.7–2.7 8 (0.5) 0.0–5.5 82 (1.8) 0.9–3.5
Age 18 years 625 (0.9) 0.7–1.3 318 (1.5) 0.8–2.6 307 (0.9) 0.7–1.3
CI, conﬁdence interval; ICU, intensive care unit; VAP, ventilator-associated pneumonia.
a Values are weighted for all studies.
Y. Zhang et al. / International Journal of Infectious Diseases 29 (2014) 84–90 89In conclusion, this meta-analysis illustrates the substantial
morbidity (particularly LOS) and mortality caused by ICU-acquired
pneumonia/VAP in China. The identiﬁcation of the organisms
causing disease in this population will help guide appropriate
prevention strategies and treatment. Additional studies are needed
to identify those patients at highest risk of developing ICU-
acquired pneumonia/VAP.
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